August 21, 2019

The Marriage of Mylan and Pfizer's Upjohn
by Patricia Van Arnum, DCAT Editorial Director
Earlier this month, Mylan and Pfizer agreed to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business. The deal is expected to close in mid-2020 and will create a new company with pro forma 2020 revenues of $19 billion to $20 billion. An inside look at the new company .   Read More

Generic-Drug Approvals: FDA OK in First Review Hard to Get
by Patricia Van Arnum, DCAT Editorial Director

A recent analysis by the US Government Accountability Office shows that only 12% of the 2,030 generic drug applications reviewed by the FDA from fiscal years 2015 through 2017 were approved in the first review cycle. What is the impact for innovator and generic-drug companies and the FDA? Read More
DCAT Value Chain Insights is produced and distributed by the Drug, Chemical and Associated Technologies Association .
To learn more, please visit www.dcat.org .